Table 2.
BC subtype | GC effects | Result |
---|---|---|
Luminal (ER+) | TR of AKT/mTOR, CCND1, CDK2, CDK6 | Block the cytoskeleton organizations and cell migrations, inhibition of proliferation |
Basal (TNBC) |
TA of ROR1, CDK1, MKP1, SGK1, PDK4, TSC22D, CCN5/WISP-2 and KLF9. TR of Bid, CD95 L, TRAIL, Bcl-xL, IRS-1, PRAG1, PLK2, CDH11, HGF, ZNF703 and SOX9 |
Increase survival, proliferation, metastatic potential, tamoxifen resistance |
Abbreviations: BC, breast cancer; Bcl-xL, BCL2-like 1; Bid, BH3 interacting domain death agonist; CCND1, cyclin D1; CCN5/WISP-2, cellular communication network factor 5; CDH11, cadherin 11; CDK1, cyclin-dependent kinase 1; CDK2, cyclin-dependent kinase 2; CDK6, cyclin-dependent kinase 6; CD95L, Fas ligand; ER, estrogen receptor; GC, glucocorticoid; HGF, hepatocyte growth factor; IRS1, insulin receptor substrate 1; KLF9, Kruppel-like factor 9; MKP1, mitogen-activated protein kinase phosphatase 1; mTOR, mammalian target of rapamycin; PDK4, pyruvate dehydrogenase kinase 4; PLK2, polo-like kinase 2; PRAG1, PEAK1-related, kinase-activating pseudokinase 1; ROR1, receptor-tyrosine-kinase-like orphan receptor 1; SGK1, serum/glucocorticoid-regulated kinase 1; SOX9, SRY-box transcription factor 9; TA, transactivation; TNBC, triple-negative breast cancer; TR, transrepression; TRAIL, TNF superfamily member 10; TSC22D, TSC22 domain family, member 3; ZNF703, zinc finger protein 703.